Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,162 matching trials from the live ClinicalTrials.gov search.
Conditions
Oesophageal Squamous Cell Carcinoma
Interventions
I-DXd, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Zirconium Zr 89 Girentuximab
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Dissection
Interventions
Endovascular aortic repair with a physician-modified endovascular graft (PMEG), TREO graft
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Dilworth, Minnesota + 3 more
Conditions
COVID-19
Interventions
PF-07304814, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Chula Vista, California • Los Angeles, California • Mather, California + 23 more
Conditions
Common Cold
Interventions
Pomegranate Concentrate (POMx), Placebo
Dietary Supplement
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Huntsville, Alabama • Melbourne, Florida • Charlottesville, Virginia
Conditions
Advanced Cancer
Interventions
Relatlimab, Nivolumab, BMS-986205, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Conditions
Advanced Solid Tumors
Interventions
PF-03446962
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina • Nashville, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

NCT00360737
Conditions
Healthy
Interventions
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Recruiting Not applicable Interventional Accepts healthy volunteers

Racial Disparities in the Expression of Paranoia

NCT07460453
Conditions
Paranoia, Psychotic Disorders
Interventions
Guided Visual Imagery Task
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Bloomington, Indiana
Not listed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Effect of Chinese Herbal Medicine on Food Allergy

NCT00602160
Conditions
Food Allergy
Interventions
FAHF-2 (TM)
Drug
Lead sponsor
Li, Xiu-Min, M.D.
Individual
Eligibility
12 Years to 45 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas • New York, New York
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Advanced Malignancies
Interventions
Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee + 1 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Repeated Cannabis Administration on Experimental Pain and Abuse Liability

NCT04576507
Conditions
Cannabis, Pain, Tolerance, Hyperalgesia
Interventions
Active Cannabis, Placebo Cannabis
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders

NCT00833599
Conditions
Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation, Vascular Anomaly, Dercum Disease
Interventions
NIRFLI with ICG
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Months and older
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
3
States / cities
Houston, Texas • The Woodlands, Texas
Conditions
Brain Neoplasms
Interventions
Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
Drug · Radiation · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Conditions
Prostate Carcinoma
Interventions
Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Tooth Discoloration
Interventions
Whitening Toothpaste, Experimental Mouthwash, Regular Fluoride Toothpaste
Drug · Device
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Melbourne, Florida
Conditions
Breast Cancer
Interventions
Mammography
Radiation
Lead sponsor
Lunit Inc.
Industry
Eligibility
Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
Non-targeted opt-out rapid HIV screening
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
16 Years and older
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Conditions
Aortic Disease
Interventions
Exclusion of thoracoabdominal lesion, Endovascular Device Implant
Procedure · Device
Lead sponsor
Rodney A. White, MD
Other
Eligibility
21 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Long Beach, California
Conditions
Retinitis Pigmentosa
Interventions
New visual processing unit (VPU) with asymmetric waveforms, New VPU with bipolar stimulation
Device
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan